首页> BMC medicine> Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.

Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Shanthini M,Crusz

第一单位： Barts Cancer Institute, Queen Mary University of London, London, UK.

作者： Shanthini M,Crusz ^[1] ; Yen Zhi,Tang ^[2] ; Shah-Jalal,Sarker ^[1] ; Warner,Prevoo ^[3] ; Irfan,Kiyani ^[4] ; Luis,Beltran ^[5] ; John,Peters ^[5] ; Anju,Sahdev ^[2] ; Axel,Bex ^[3] ; Thomas,Powles ^[1] ; Marco,Gerlinger ^[6]

作者单位： Barts Cancer Institute, Queen Mary University of London, London, UK. ^[1] Department of Radiology, St Bartholomews Hospital, London, UK. ^[2] Departments of Surgical and Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[3] Institute of Nuclear Medicine, University College Hospital, London, UK. ^[4] Department of Surgery, Whipps Cross Hospital, London, UK. ^[5] Centre for Evolution and Cancer, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK. marco.gerlinger@icr.ac.uk.;The Royal Marsden Hospital, London, UK. marco.gerlinger@icr.ac.uk. ^[6]

关键词 Anti-angiogenic treatment Drug resistance Intratumour heterogeneity Kidney cancer RECIST